It can be concluded that EAM-2201 has the opportunity to result in in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is also evaluated in pooled human liver microsomes. Notes: This opportunity was made for experiments of MAX period deformation, with specific interest paid https://homerd950ndr2.theideasblog.com/profile